Related Experiment Video
Updated: Aug 9, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Biologic Therapies for Moderate to Severe Asthma in the Pediatric Population: A Practice Update
1Yale University, School of Medicine, Section of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine, New Haven, CT, USA.
Insights
New biologic therapies offer additional treatment options for children with moderate to severe asthma. These advanced treatments, alongside inhaled corticosteroids, help manage childhood asthma effectively.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Nursing Practice
Background:
- Asthma is a prevalent condition in childhood.
- Inhaled corticosteroids have been the primary long-term control treatment.
- Biologic therapies represent a newer advancement for specific pediatric asthma cases.
Purpose of the Study:
- To summarize current biologic therapies for pediatric asthma.
- To guide nursing professionals on the appropriate use of these therapies.
- To inform care planning for children with moderate to severe asthma.
Main Methods:
- Literature review of available biologic therapies.
- Analysis of indications for pediatric asthma management.
- Synthesis of current treatment guidelines.
Main Results:
- Biologic therapies provide new avenues for uncontrolled moderate to severe pediatric asthma.
- Specific criteria guide the selection of biologic agents.
- Nursing plays a crucial role in administration and monitoring.
Conclusions:
- Proper diagnosis and selection of asthma therapies are vital.
- Biologic therapies expand treatment options for children.
- Effective management by nursing professionals enables active lives for children with asthma.
Introduction:
Asthma is a common childhood condition. Up until recent years, the mainstay of long-term control treatment has been inhaled corticosteroids. While inhaled corticosteroids are very effective for most children with asthma, with the introduction of biologic therapies, additional options now exist for children with uncontrolled moderate to severe asthma.
Purpose:
The purpose of this Practice Update is to provide nursing professionals with a summary of the biologic therapies currently available for the pediatric population and, to describe when they are indicated for inclusion in the plan of care for children with moderate to severe asthma.
Conclusion:
By properly diagnosing asthma, and, selecting and administering appropriate asthma therapies, nursing professionals can help children with moderate to severe asthma lead healthy and active lives.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...